Back to Bills

Lower Patient Coinsurance For Negotiated Drugs

Full Title:
Protecting Patient Access to Cancer and Complex Therapies Act

Summary#

This bill requires drug makers to pay a quarterly rebate to Medicare when a drug subject to a negotiated maximum fair price (MFP) would otherwise be paid for under Medicare Part B at a higher amount. It keeps Medicare Part B provider payments based on the current ASP+6 method (average sales price plus 6 percent) but makes patient coinsurance based on the lower MFP+6 amount. Rebates go into the Federal Supplementary Medical Insurance (SMI) Trust Fund and civil penalties apply for noncompliance.

  • Main change: Manufacturers must pay a rebate equal to the difference between (a) the ASP+6 amounts (payment and coinsurance) and (b) the MFP+6 amounts, multiplied by units furnished for the quarter.
  • Patient cost-sharing: Beneficiary coinsurance for affected drugs is calculated using MFP+6 (the lower amount), not ASP+6, so patients should owe a smaller coinsurance at the point of service.
  • Provider payments: Medicare payments to providers remain based on ASP+6.
  • Timing and reporting: HHS (the Secretary) must report quarterly drug unit counts and calculated amounts to manufacturers; manufacturers must pay the rebate within 30 days of receiving that information.
  • Money flows and penalties: Rebates go into the SMI Trust Fund. Existing civil money penalties apply for failures to comply.
  • Other legal changes: The bill excludes these MFP rebates from ASP calculations and adds related conforming changes for outpatient and ambulatory surgical center payment rules and Medicaid rebate reporting.

What it means for you#

  • Medicare Part B patients who get covered cancer or complex therapies
    • Your coinsurance (usually 20%) for a drug on the “selected” list would be calculated on the lower MFP+6 amount. This could mean a lower out-of-pocket payment at the time you receive the drug.
  • Doctors, hospitals, and clinics
    • Medicare payment to the provider stays based on ASP+6. Clinics will need to apply a coinsurance percent derived from the MFP+6 calculation when collecting patient cost-sharing.
    • Billing and reconciliation systems may need updates to use different bases for payment versus coinsurance.
  • Drug manufacturers
    • If you have an agreement under the referenced negotiation program and an MFP is in effect, you must pay quarterly rebates equal to the calculated difference times units furnished. You must pay within 30 days after receiving the Secretary’s report.
  • Medicare program and taxpayers
    • Medicare will receive additional rebate dollars into the SMI Trust Fund. How that changes net program spending is not specified in the bill text.
  • Medicaid and state programs
    • The bill makes a small change to Medicaid rebate disclosure language to account for multiple rebates; practical effects on state programs are not detailed.

Expenses#

No publicly available information on a formal cost estimate or fiscal note is included with the bill text.

  • The bill directs rebates to the SMI Trust Fund, so Medicare would receive additional receipts from manufacturers. How much and how that affects net Medicare spending is not stated.
  • HHS must produce quarterly reports and track payments. This could increase administrative and IT costs for Centers for Medicare & Medicaid Services (CMS), though no estimate is given.
  • Manufacturers will have compliance and accounting costs to calculate, report, and pay quarterly rebates and to respond to civil money penalty rules if they fail to comply.
  • There may be indirect or downstream costs or savings (for example, changes in patient access, manufacturer pricing decisions, or provider billing systems), but the bill text does not provide numbers.

Proponents' View#

The bill appears intended to address the gap between negotiated maximum fair prices and existing Medicare Part B payment and coinsurance rules. Possible arguments for the bill based on the text:

  • It could lower patients’ out-of-pocket cost for selected drugs by calculating coinsurance on the lower MFP+6 amount rather than ASP+6.
  • It keeps provider payments at the ASP+6 level, avoiding a sudden reduction in provider revenue for administering high-cost drugs.
  • It makes manufacturers return the difference (via rebates) when the MFP is lower than ASP, so Medicare captures savings from the negotiated price.
  • It deposits rebates into the SMI Trust Fund, providing a clear destination for recovered funds.
  • It includes enforcement (civil money penalty) to encourage compliance.

Opponents' View#

The bill text raises several practical and implementation questions that could be concerns:

  • One concern is administrative complexity. The Secretary must calculate and report quarterly counts and payment differences, and providers, manufacturers, and payers must reconcile separate payment and coinsurance bases.
  • It is unclear how quickly systems used by providers and manufacturers can adapt; the 30-day payment window may be challenging for some manufacturers to meet.
  • The bill does not include a public fiscal estimate, so the net effect on Medicare spending, patient costs, and the SMI Trust Fund is not stated.
  • Excluding these MFP rebates from ASP calculations could affect future ASP-based pricing measures or reporting, but the bill does not explain the long-term pricing impact.
  • The bill does not describe how interactions with other rebate programs (for example, Medicaid rebates) will be handled in practice beyond a narrow disclosure change; coordination issues could arise.
  • The text does not address possible manufacturer responses (such as pricing or supply decisions); any such effects are not specified and remain uncertain.

What is unclear: The bill defines mechanics for rebates, coinsurance, and deposit of funds, but it does not provide a fiscal estimate, detailed operational guidance, or analysis of longer-term effects on pricing, manufacturer behavior, or provider billing systems.